- Home
- PRTA vs LENZ Comparison
PRTA vs LENZ Comparison
Compare PRTA & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTA | LENZ |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 527.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRTA | LENZ |
|---|---|---|
| Price | $9.12 | $15.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $18.86 | ★ $56.25 |
| AVG Volume (30 Days) | 729.9K | ★ 1.3M |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,786,000.00 | ★ $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $819.08 | $204.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $14.91 |
| 52 Week High | $16.67 | $50.40 |
Technical Indicators
Market Signals| Indicator | PRTA | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 27.44 |
| Support Level | $8.95 | $15.36 |
| Resistance Level | $9.47 | $17.51 |
| Average True Range (ATR) | 0.37 | 0.98 |
| MACD | -0.03 | 0.26 |
| Stochastic Oscillator | 22.61 | 8.68 |
Price Performance
Historical ComparisonAbout PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.